PL317197A1 - Compositions for and method of treating sclerosis multiplex - Google Patents

Compositions for and method of treating sclerosis multiplex

Info

Publication number
PL317197A1
PL317197A1 PL95317197A PL31719795A PL317197A1 PL 317197 A1 PL317197 A1 PL 317197A1 PL 95317197 A PL95317197 A PL 95317197A PL 31719795 A PL31719795 A PL 31719795A PL 317197 A1 PL317197 A1 PL 317197A1
Authority
PL
Poland
Prior art keywords
compositions
sclerosis multiplex
treating sclerosis
treating
multiplex
Prior art date
Application number
PL95317197A
Other languages
English (en)
Inventor
Di-Hwei Hsu
Dawn Smilek
Jia Dong Shi
Original Assignee
Immulogic Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immulogic Pharma Corp filed Critical Immulogic Pharma Corp
Publication of PL317197A1 publication Critical patent/PL317197A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rehabilitation Therapy (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PL95317197A 1994-05-10 1995-05-04 Compositions for and method of treating sclerosis multiplex PL317197A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24124694A 1994-05-10 1994-05-10
US32822494A 1994-10-25 1994-10-25

Publications (1)

Publication Number Publication Date
PL317197A1 true PL317197A1 (en) 1997-03-17

Family

ID=26934122

Family Applications (1)

Application Number Title Priority Date Filing Date
PL95317197A PL317197A1 (en) 1994-05-10 1995-05-04 Compositions for and method of treating sclerosis multiplex

Country Status (11)

Country Link
EP (1) EP0758902A1 (fr)
JP (1) JPH10500109A (fr)
AU (1) AU2470595A (fr)
CA (1) CA2189990A1 (fr)
CZ (1) CZ329596A3 (fr)
HU (1) HUT76099A (fr)
IL (1) IL113661A0 (fr)
PL (1) PL317197A1 (fr)
SI (1) SI9520059A (fr)
SK (1) SK145896A3 (fr)
WO (1) WO1995030435A2 (fr)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI9520118A (sl) * 1994-10-25 1998-08-31 Immulogic Pharmaceutical Corporation Sestavki in zdravljenje multiple skleroze
US6156535A (en) 1995-08-04 2000-12-05 University Of Ottawa Mammalian IAP gene family, primers, probes, and detection methods
AU5671196A (en) * 1996-03-28 1997-10-17 Immulogic Pharmaceutical Corporation Myelin oligodendrocyte glycoprotein peptides and uses thereof
WO1998006861A2 (fr) * 1996-08-15 1998-02-19 Agrivax Incorporated Administration d'antigenes tolerogeniques via des plantes comestibles ou des produits derives de plantes
AUPP823999A0 (en) * 1999-01-20 1999-02-11 University Of Queensland, The A treatment
US20020025304A1 (en) * 2000-06-16 2002-02-28 Croze Edward M. Novel interferon for the treatment of multiple sclerosis
BRPI0113400B1 (pt) * 2000-08-21 2018-05-15 Apitope Technology Bristol Método para seleção de peptídeo
GB0202399D0 (en) * 2002-02-01 2002-03-20 Univ Bristol Peptide
ES2325660T3 (es) 2002-03-27 2009-09-11 Aegera Therapeutics Inc. Oligomeros nucleobasicos de iap no codificantes y usos de los mismos.
US8012944B2 (en) 2003-10-30 2011-09-06 Pharmascience Inc. Method for treating cancer using IAP antisense oligomer and chemotherapeutic agent
BG66517B1 (bg) 2008-04-08 2016-02-29 Tigo Gmbh Супресор на ендогенния човешки гама - интерферон
BG1430U1 (bg) * 2010-06-25 2011-04-29 Иван ИВАНОВ Фармацевтично средство
BG67190B1 (bg) 2017-03-29 2020-11-16 Tigo Gmbh Анти-гама мутантен протеин срещу ендогенния човешки гама интерферон

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69331501T2 (de) * 1992-04-09 2002-08-29 Autoimmune, Inc. Unterdrückung der Proliferation von T-Zellen mittels Peptidfragmenten des basischen Proteins aus Myelin
WO1994004121A1 (fr) * 1992-08-17 1994-03-03 Autoimmune, Inc. Suppression par un antigene tiers d'une maladie neurologique associee a un retrovirus

Also Published As

Publication number Publication date
WO1995030435A3 (fr) 1995-12-07
WO1995030435A2 (fr) 1995-11-16
CA2189990A1 (fr) 1995-11-16
EP0758902A1 (fr) 1997-02-26
HU9603116D0 (en) 1997-01-28
JPH10500109A (ja) 1998-01-06
HUT76099A (en) 1997-06-30
SK145896A3 (en) 1997-05-07
CZ329596A3 (en) 1997-05-14
AU2470595A (en) 1995-11-29
IL113661A0 (en) 1995-08-31
SI9520059A (en) 1997-08-31

Similar Documents

Publication Publication Date Title
PL320487A1 (en) Haemorrhoidal compositions and method of applying them
US5443636B1 (en) Composition for and method of pumping concrete
PL324970A1 (en) Method of and composition for treating asthma
PL324091A1 (en) Compositions and procedure for treating sclerosis multiplex
PL333364A1 (en) Novel compounds and method of using them
AP9300598A0 (en) Compositions and method for waste treatment
PL327617A1 (en) Compositions for and methods of treating osseous insufficiency
PL329893A1 (en) Method of and compositions for treating and preventing hyperuricaemia
EP0758242A4 (fr) Compositions et methodes de traitement des infections dues au cytomegalovirus (cmv)
GB9520615D0 (en) Method of preventing bone loss
PL317197A1 (en) Compositions for and method of treating sclerosis multiplex
ZA931778B (en) Method and composition for the treatment of osteoporosis
PL321204A1 (en) Compositions for peroxiding creatine fibres and method of using such compositions
GB9517111D0 (en) Surface-coating composition and method of application
AU4104093A (en) Method and compositions for treatment of pyonecrotic processes
GB2296718B (en) Method for infrared-activated curing of polyorganosiloxane compositions
PL314588A1 (en) Application of pentoxyphyline in treatment of sclerosis multiplex
PL326924A1 (en) Compositions for and methods of preventing and treating mouth mucositis
CS61691A2 (en) Composition for dung-water treatment and method of dung-water treatment
AU7379296A (en) Method and composition for treatment of osteoporosis
GB9415902D0 (en) Method of treatment
GB9407335D0 (en) Method of treatment
PL306631A1 (en) Match-head composition and method of obtaining same
PL314367A1 (en) Preparation for use in treating sclerosis multiplex and method of obtaining same
PL322998A1 (en) Phospholipidic composition and and method of obtaining same